Cartesian Therapeutics
RNAC
92 hedge funds and large institutions have $63.2M invested in Cartesian Therapeutics in 2023 Q2 according to their latest regulatory filings, with 21 funds opening new positions, 31 increasing their positions, 20 reducing their positions, and 21 closing their positions.
2,480% more call options, than puts
Call options by funds: $129K | Put options by funds: $5K
55% more repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 20
0.21% more ownership
Funds ownership: 1.02% → 1.23% (+0.21%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 21
1% less funds holding
Funds holding: 93 → 92 (-1)
8% less capital invested
Capital invested by funds: $69.1M → $63.2M (-$5.85M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.53M |
| 2 |
AG
Artal Group
Luxembourg
|
+$5.07M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$2.22M |
| 4 |
State Street
Boston,
Massachusetts
|
+$1.84M |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.38M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MFS
Mirabella Financial Services
London,
United Kingdom
|
-$4.03M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$2.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
-$1.81M |
| 4 |
ECM
Endurant Capital Management
San Mateo,
California
|
-$1.77M |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$961K |
RNAC Hedge Fund Activity: Q2 2023 in Review
92 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Cartesian Therapeutics (RNAC) for Q2 2023, worth a combined $63.2M — down 8.5% from $69.1M a quarter earlier.
Fund positioning in RNAC was balanced in Q2 2023: 21 funds opened new positions, 21 closed out, 31 added to existing stakes and 20 trimmed.
The largest buyer was BlackRock, adding an estimated $6.53M. The largest seller was Mirabella Financial Services, exiting entirely with an estimated $4.03M sold.
- 92 institutional investors held Cartesian Therapeutics (RNAC) as of Q2 2023, down from 93 in Q1 2023.
- Funds reported $63.2M of Cartesian Therapeutics stock for Q2 2023, down 8.5% quarter-over-quarter.
- 21 funds opened new Cartesian Therapeutics positions in Q2 2023 and 21 closed out, a net change of 0 holders.
- The largest Cartesian Therapeutics buyer in Q2 2023 was BlackRock, an estimated $6.53M added.
- The largest Cartesian Therapeutics seller in Q2 2023 was Mirabella Financial Services, an estimated $4.03M sold.
Based on aggregated 13F filings for Q2 2023.